Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (91050)	4/1/2000 12:38:00 AM
From: debra vogt	Respond to of 120523

Friday March 31, 7:01 pm Eastern Time Andrx, shareholder files to sell 3.675 mln shares WASHINGTON, March 31 (Reuters) - Andrx Corp. (NasdaqNM:ADRX - news), which formulates and sells oral drugs including ulcer treatments, filed on Friday to sell a little more than 3 million shares while a stockholder plans to sell 674,158 shares. The company said it would use the net proceeds from the sale of its shares to expand its manufacturing, research and development and administrative facilities, acquisitions, working capital and other general corporate purposes. It will not receive any of the funds from the sale of shares by the stockholder, Watson Pharmaceuticals Inc. (NYSE:WPI - news). The underwriters, led by Banc of America Securities LLC and Bear, Stearns & Co. Inc., have been granted the option to buy an extra 551,250 shares to cover over-allotments. Shares in the Fort Lauderdale, Fla.-based company closed up 10-3/8 to 115-1/2 on Nasdaq.